A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2008 |
Reihe/Periodikum: | Annals of Oncology ; volume 19, issue 4, page 734-738 ; ISSN 0923-7534 |
Verlag/Hrsg.: |
Elsevier BV
|
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28586753 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1093/annonc/mdm607 |